Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Dimopoulos, Meletios A.
- Moreau, Philippe
- Augustson, Bradley
- Castro, Nelson
- Pika, Tomas
- Delimpasi, Sosana
- Maiolino, Angelo
- Reiman, Tony
- Martinez-Lopez, Joaquin
- Martin, Thomas
- Mikhael, Joseph
- Yong, Kwee
- Risse, Marie-Laure
- Asset, Gaelle
- Marion, Sylvia
- Hajek, Roman
Grupos
Abstract
[No abstract available]
Datos de la publicación
- ISSN/ISSNe:
- 0361-8609, 1096-8652
- Tipo:
- Article
- Páginas:
- 15-19
- DOI:
- 10.1002/ajh.26602
- PubMed:
- 35604280
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 2,600 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
AMERICAN JOURNAL OF HEMATOLOGY WILEY
Citas Recibidas en Web of Science: 21
Documentos
- No hay documentos
Filiaciones
Keywords
- bortezomib; carfilzomib; dexamethasone; isatuximab; lenalidomide; antineoplastic agent; monoclonal antibody; age; aged; arthralgia; bronchitis; cancer recurrence; cancer staging; constipation; controlled study; coughing; diarrhea; drug efficacy; drug response; drug safety; drug withdrawal; dyspnea; fatigue; human; hypertension; infusion related reaction; Letter; line of treatment; major clinical study; minimal residual disease; multiple cycle treatment; multiple myeloma; nausea; pneumonia; progression free survival; treatment duration; upper respiratory tract infection; vomiting; tumor recurrence; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Multiple Myeloma; Neoplasm Recurrence, Local
Campos de Estudio
Cita
Dimopoulos MA,Moreau P,Augustson B,Castro N,Pika T,Delimpasi S,DE LA RUBIA J,Maiolino A,Reiman T,Martinez J,Martin T,Mikhael J,Yong K,Risse M,Asset G,Marion S,Hajek R. Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Am. J. Hematol. 2022. 98. (1):p. 15-19. IF:12,800. (1).
Portal de investigación